What must your pharmacist establish? · BPC-157 TB-500
What does Wolverine legal status mean for your pharmacy?
Research on injured animals didn't make these ingredients approved medicines. FDA's page dated April 22, 2026 lists withdrawn pharmacy requests outside Category 2; that change doesn't settle safety.
What does the FDA listing say about BPC-157 TB-500?
Researchers studied the BPC-157 TB-500 ingredients separately, hoping to help injured tissue. Those animal results don't answer the Wolverine legal status question for your pharmacy.
July 23-24, 2026: FDA advisers discussed adding the ingredients to a permitted pharmacy list [15]. The list concerns ingredients for medicines specially prepared for patients.
FDA staff wanted both ingredients kept off the list; votes weren't published as of September 2026. A meeting discussion doesn't give your pharmacist permission to make the proposed medicine.
September 29, 2023: both ingredients entered FDA's Category 2 over possible serious harm [13]. The safety warning concerned patients, including people thinking about care for an injury like yours.
The two BPC-157 forms listed were “free base” and “BPC-157 acetate.” The first is BPC-157 without added salt; the second is a salt form, a different chemical preparation.
A salt form isn't table salt, and neither form has approval for treatment. Ask your pharmacist which form is proposed and how the contents were checked.
FDA also named TB-500, made by copying a short piece taken from Thymosin beta-4. Findings about the whole protein don't approve that shorter copy for your injury.
FDA's page current as of April 22, 2026 lists both pharmacy requests as withdrawn [13]. The ingredients aren't in Category 2 now because those requests were withdrawn; FDA hasn't dated that change.
The people making the requests stopped seeking permission through those requests. That doesn't show the ingredients became safe or that pharmacies gained permission to use them.
The 2023 Category 2 listing and July 2026 agenda concerned both ingredients. I'd ask which rule allows your pharmacy to prepare each ingredient before discussing a prescription.
How can a pharmacy establish permission for an ingredient?
U.S. law treats individual prescriptions and larger batches of specially prepared medicine differently [14]. A licensed doctor or pharmacy may make specially prepared medicine for a single patient with a valid prescription.
Your pharmacy also has to find a rule permitting each proposed ingredient [14]. Each ingredient needs an official quality standard, a place in an approved drug, or FDA's permitted listing.
The standard sets tests of strength, contents, and cleanliness; a prescription doesn't replace those checks. Ask your pharmacist which rule permits the ingredients in the proposed treatment.
FDA-registered businesses making larger batches have their own ingredient rules. Being registered doesn't give a business permission to use every ingredient.
The pharmacy requests were withdrawn, so both ingredients left Category 2. That change doesn't establish that your pharmacy can prepare the proposed medicine.
FDA warned that pharmacies using Category 2 ingredients could face enforcement, such as orders to stop [13][14]. For Category 1, FDA could wait before ordering pharmacies to stop while reviewing ingredients without those identified serious risks.
That temporary delay could let some pharmacies continue preparing medicine during review; neither ingredient qualifies now. Category 2 ingredients weren't offered that delay, and the group names don't prove benefit or safety.
For BPC-157 and TB-500, FDA warned of harmful immune-system reactions with certain treatment methods [13]. The immune system fights infection; uncertain ingredients and unwanted material could also cause harm.
Advisers offer opinions, and FDA decides which ingredients enter the permitted list [14][15]. Ask your pharmacist which ingredient rule allows the proposed medicine for you.
Did the withdrawn requests settle what pharmacies may prepare?
September 29, 2023: FDA added the two ingredients to Category 2 over possible serious harm [13]. Withdrawn pharmacy requests later took the ingredients outside Category 2, without proving safety or granting permission.
July 23-24, 2026: advisers discussed both ingredients, but their votes haven't been published [15]. Your pharmacist still needs an ingredient rule allowing the proposed medicine.
Does a changed safety listing mean FDA approved treatment?
BPC-157, TB-500, and the mixture aren't approved treatments. September 29, 2023: the two ingredients entered Category 2 because of possible serious harm [13][14].
Withdrawal of the requests put the ingredients outside Category 2, without showing that the safety concerns ended. Your pharmacist still needs a rule allowing the preparation.
July 2026: FDA staff opposed adding the ingredients to the permitted list [15]. The discussion doesn't establish approval for your proposed treatment.
What would a BPC-157 visit and pharmacy check involve?
An examination by someone licensed to prescribe usually precedes specially prepared medicine [14]. Your doctor assesses whether that medicine fits the injury and needs you're discussing.
A licensed pharmacy prepares the medicine, or an FDA-registered business supplies larger batches [14]. A video visit still needs a valid prescription and ingredients allowed for that preparation [14].
FDA lists requests to permit pharmacy use of BPC-157 and TB-500 as withdrawn [14]. Withdrawal put both ingredients outside Category 2; it didn't establish safe treatment or pharmacy permission.
FDA still states its safety concerns, and the ingredient rules still apply. Removal from Category 2 alone can't show that your pharmacy may make the medicine.
Ask who will examine your injury and which pharmacy would prepare any medicine. Also ask who follows your progress, how to report problems, and what visits would cost.
Nobody here supplies these substances or provides care for your injury. Your own medical and legal choices need someone qualified to assess your circumstances.
Does a video visit change the BPC-157 ingredient rules?
Specially prepared medicine generally needs an examination, prescription, and licensed pharmacy or registered batch maker [14]. A visit by video still leaves your pharmacy needing to establish ingredient permission.
FDA lists the BPC-157 pharmacy request as withdrawn; the ingredient is outside Category 2 [13][14]. FDA keeps the safety concerns and hasn't said that withdrawal permits preparation for you.
What can your pharmacist confirm about preparing BPC-157?
Someone licensed to prescribe generally examines you before writing a prescription [14]. A licensed pharmacy or registered batch maker must also meet the ingredient rules.
The BPC-157 pharmacy request was withdrawn, placing the ingredient outside Category 2 [13]. FDA hasn't said which preparations the change allows your pharmacy to make.
A prescription alone doesn't resolve that question about the ingredient. Ask your pharmacist which rule allows the proposed medicine and how the rule was checked.
Has FDA approved either ingredient or the Wolverine mixture?
FDA hasn't approved BPC-157, TB-500, or the mixture to treat your injury [13]. The withdrawn pharmacy requests put both ingredients outside Category 2, without establishing safety.
July 2026: advisers discussed the ingredients, but no published result settled pharmacy permission [15]. Your doctor and pharmacist still need to assess the actual proposed care.
What do sports rules say about these ingredients?
Neither ingredient has FDA treatment approval; both entered Category 2 over possible serious harm [13]. Withdrawing the pharmacy requests didn't establish that patients could safely receive treatment.
Both ingredients are banned in sport by the World Anti-Doping Agency. BPC-157 is banned as unapproved; TB-500 / Thymosin Beta-4 is banned among peptides and substances that encourage growth.